Oxycodone versus dezocine for postoperative analgesia in patients with cervical cancer treated with radical surgery.

OBJECTIVE: The aim of this study was to evaluate oxycodone versus dezocine for postoperative analgesia in patients with cervical cancer treated with radical surgery.

MATERIALS AND METHODS: Fifty-one cases of cervical cancer treated with radical surgery were included in the present study and divided into oxycodone group (n = 26) and dezocine group (n = 25). Patients in the oxycodone group were given with oxycodone 1 mg/kg plus tropisetron 0.1 mg/kg diluting to 100 ml by 0.9% saline for patient-controlled intravenous analgesia (PCIA) after surgery. Moreover, patients in the dezocine group were given with dezocine 0.6 mg/kg plus tropisetron 0.1 mg/kg diluting to 100 ml by 0.9% saline for PCIA after surgery. The visual analog scale (VAS) and Ramsay sedation score of the two groups were recorded in the time point of 4, 8, 12, 24, and 48 h after surgery. The adverse event-related drugs were recorded and compared between the two groups.

RESULTS: The VAS score was significantly lower in oxycodone group compared to dezocine group in the time point of 4, 8, 12, 24, and 48 h (Pall < 0.05). The Ramsay score at time point of 4, 8, 12, 24 h, and 48 h were obviously higher in oxycodone group than those in dezocine group (P < 0.05) which indicated that the sedative effect in oxycodone group was superior to dezocine. For oxycodone group, there were six cases (23.08%) with nausea and one case (3.85) with vomiting in the treatment procedure. Moreover, for dezocine group, there were one case (4.00%) with nausea, two cases (8.00%) with vomiting, and two cases (8.00%) with dizzy in the treatment procedure. There was no statistical difference of adverse event risk between the two groups (P > 0.05).

CONCLUSION: Oxycodone postoperative analgesia is superior to dezocine for patients with cervical cancer treated with radical surgery.